** Citi downgrades drugmaker AbbVie ABBV.N to "neutral" from "buy"; cuts PT to $205 from $210
** New PT represents 9.04% upside to stock's last close
** "While current fundamentals are solid, we suspect that the share impact from quarterly surprises could diminish going forward, especially as investors increasingly shift more focus to the pipeline," brokerage says
** Citi says co's drugs in late-stage development comprise "mostly label expansions that offer less opportunity than those already approved"
** ABBV shares down 0.9% at $186.42 premarket
** Co is seen as having higher policy risks than its peers due to potential PBM reform and U.S. President Donald Trump's proposed order Most Favored Nation pricing or international reference pricing for drugs, which could affect its market safety position, Citi says
** As of last close, stock up 5.8% YTD
(; Editing by Shreya Biswas)
((shreya.biswas@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。